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Summary: The use of a new monoclonal enzyme immuiioassay (EIA) for the carcinoembryonic antigen'
(CEA) (Enzymun^Test® CEA) was eväluated in a multi-centre study. Fifteen different laboratories participated
in the study. Data fröm the investigation were analysed in terms of precision, sensitivity, specificity and
correlation with other test methods. The intra-assay coefficient of Variation was between 1.3% at 23.0 g/l
CEA and 13.9% at l^g/l CEA. Iiiter-assay reproducibility ranged from 3.6% to 19.2%. The apparent
sensitivity of the new EIA for CEA was approx. 0.5 g/l CEA. The findings indicate that lipaemic and
haemolytic sera and samples taken from icteric, rheumatic and dialysis patients did not have any influence
on the results. There was no evidence that drugs commonly used in the treatment of carcinoma patients
have any influence on the assay results. A good correlation between the new EIA for CEA and six other
CEA enzyme "immunoassay or radioiinmunoassay methods was registered. These results seem to be of
significance in particiflar for the monitoring of therapy for carcinoma patients. The new EIA for CEA
exhibits a high degree of sensitivity, specificity and reproducibility.
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Introduction
Carcinoembryonic antigen (CEA) is a glycoprotein
consisting of a polypeptide chain with a molecular
weight of 180 kD. It has a carbohydrate content of
40 to 60%. The protein moiety of CEA is a single
polypeptide chain with multiple intrachain disulphide
bonds. The pure peptide chain consists of some 800
amino acids (1). The physiological function of CEA
is not known.
CEA is normally detectable only in very low concen-
trations in the serum of healthy men and women.
Pathologically raised CEA serum levels are encoun-
tered in conjunction with CEA-producing tumours.
CEA has been used for monitoring patients with
colorectal carcinoma, and its role äs a tumour marker
and äs diagnostic tool in this disease is well docu-
mented (2). Recent reports suggest that CEA may
also be used äs a tumour marker for cancers other
than colorectal (3). It was also noted to be of use in
gynaecological tumours (4—6).
Since the first report of a radioimmunoassay System
(7), other radioimmunological methods, in addition
to enzyme immunoassay Systems, have been de-
scribed. Some studies show a strong correlation be-
tween different assay Systems (8, 9, 10), others (11,
12) reveal a low-degree of correlation or even lack of
comparability.
The aim of this multi-centre study was to investigate
the sensitivity, the specificity and reproducibility of
a new CEA enzyme immunoassay (EIA) using mono-
clonal antibodies (Enzymun-Test® CEA). In addition,
the investigation was aimed at comparing CEA serum
levels estimated by this new EIA with other enzyme
immunoassay and radioimmunoassay methods.
This multi-centre form of organization was used to
ascertain whether data obtained with this new EIA
is comparable with results obtained by other assay
Systems. We were prompted to investigate this ques-
tion, since patients in whom serial CEA determina-
tions are indicated are not necessarily investigated by
the same laboratory. Another aim of the multi-centre
study was to define reference ranges, to describe CEA
serum levels in various malignancies and to evaluate
whether this new CEA EIA method can be used for
monitoring carcinoma patients.
Materials and Methods
Immunoassay teehnology
The assay is based on the Sandwich EIA principle using solid
phase and enzyme-labelled monoclonal antibodies (13).
Reagents
Test kit "Enzymun-Test® CEA", cat. no. 204501, from
Boehringer Mannheim, D-6800 Mannheim, containing incuba-
tion buffer 100 mmol/1 acetate buffef, pH 5.7, anti-CEA-peroxi-
dase-conjugate > 100 U/l; Substrate buffer 100 mmöl/1 phos-
phate-citrate-buffer, pH 4.4; 3.2 mmol/1 sodium perborate, 1.9
mmol/1 di-ammonium 2.2'-azino-bis (3-ethylbenzothiazoline-6-
sulphonate) (ABTS®); 5 Standards CEA hl horse serum, cpn-
centration 0-55 g/l; cpntrol serum, CEA in horse serum; 100
plastic vials coated with CEA antibody, binding capacity > 200
ng CEA per vial. The working solution is prepared according to
the manufacturer's instructions.
Assay protocol
1. Samples or Standards (100 ) were incübated with l ml antl··
CEA-conjugate solution in the plastic tübes for 2 hours at
20-25°C.
2. Vial contents were aspirated and plastic tubes were rinsed
three times with tap water.
3. ABTS® Substrate solution (l ml) was added and incubatipn
continued for another 60 inimites at 20-25 °C.
4. Absorbance was read at 405 mn and CEA concentrations
were calculated from the calibration curve.
Standard calibration
The working Standards of the test kit were prepared in horse
serum. They were calibrated agäinst the first international refer-
ence preparation of CEA (14) of the National Institute for
Biological Standards and Control, Holly Hüll, Hampstead, Lon-
don, NW3 6RB.
Antigen preparation
CEA was purified from an adeno-carcinoma of the colon,
according to the method of Krupey et al. (15) modified äs
described by Krantz et al. (16). The purity of the CEA prepara-
tion was greater than 90% äs judged by analytical pölyacryl-
amide gel electrophoresis.
Monoclonal antibody production
Immunization
The procedure ofAccolla et al. (17) was used. Balb/c mice were
immunized twice with 15 ng purified CEA in complete Freunds
adjuvant per injection in intervals of 14 weeks. One day after
the second injection the mice were immunized with 100 g CEA
in saline intraperitoneally. The following day the mice received
a final booster dose of 150 g CEA in saline mtraperitoneally.
Three days later the spieen cells were fused.
Fusion
Spleen cells of immunized Balb/c mice were fused with mouse
myeloma cells P3-NS1/1-AG4 using polyethylene glycol (PEG)
4000 (volume fraction 0.40). The resulting cell Suspension was
distributed in the wells of rive-Po-well^plates. The culture super-
natants were screened for CEA antibody prodüction.
The positive cultures were cloned by cytofluorographic Separa-
tion into five 96-well plates .per positive well of the primary
culture. The cells of a positive hybridoma clone were injected,
5 1 6 cells, into a pristan-primed Balb/c moüse for ascites
induction.
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Purification of immunoglobulins
The immunoglobulins were separated from albumin and other
body fluid proteins by tbree-fold ammonium sulphate frac-
tionation and subsequent DEAE cellulose chromatography.
Characterization of the antibodies
The antibodies Tu 2 and 3 used in the test kit, were analysed
by isoelectrofocusing, immunoglobulin sub-class determination
and competitive RIA. Both belong to the IgG sub-class IgG
l/K. Tu 2 has an affinity constant Ka of 2.5 χ l O10, Tu 3 of
I x l O10 s measured in 0.02 mol/1 Tris buffer according to
Steward & Petty (18). The reactivity with non-specific cross-
reacting antigen (NCA) (19) is less than 0.05% for Tu 2 and
less than 0.005% for Tu 3. Granulocytes do not react with
either antibody.
Evaluation procedure
Enzymun-Test® CEA was assayed in 15 laboratories. All serum
samples were determined in duplicate.
Four laboratories followed the manual test procedure, 11 lab-
oratories were equipped with Enzymun-Test® System ES 22
(20), a modular batch analyser System (ES 22, Boehringer
Mannheim GmbH).
Besides one self-developed CEA radioimmunoassay the follow-
ing kits were used:
RIA-gnost® CEA, Behringwerke AG; CEA EIA Test, R che;
Abbott CEA-EIA polyclonal and
Abbott CEA monoclonal, Abbott laboratories; Phadebas CEA
PRIST® radioimmunoassay, Pharmacia GmbH.
For the interassay precision, Lyphochek® Immunoassay control
serum (human) levels I (A), II (B), III (C), ΒΙΟ-RAD ECS
Division, and the control serum of Enzymun-Test® CEA (D)
were used.
Results
Precision
The intra-assay precision determined in human sera
with concentrations of up to 30.3 μ§/1 CEA is shown
in figure 1. The coefficients of Variation ranged ffom
1.3% at 23.0 μg/l CEA to 13.9% at 1.3 μκ/l CEA.
15
10
.0 10 20 30
Fig. 1. Intra-assay precision in CEA concentration from 1.3 —
30.3 μ§/1. The results of all laboratories are summarized
in mean values ± 2 SD (n = 10).
The inter-assay reproducibility was determined by 15
participants from duplicate measurements of 4 com-
mercial control sera over ten days. The overall inter-
assay coefficients of Variation ranged from 3.6—
19.2% (tab. 1).
Tab. 1. Inter-assay precision from control sera. Mean (x) of
all means with the Standard deviation (SD) and the
coefficient of Variation (CV) of n experiments collected
from all laboratories.
Sample SD CV
Control A
Control B
Control C
Control D
2.6
14.1
21.5
8.3
0.48
0.59
1.05
0.30
18.5
4.2
4.9
3.6
Linearity and influence of diluent
A patient specimen containing 41 μg/l CEA was di-
luted with increasing amounts of CEA-free human
serum and the zero Standard (horse serum) of the kit.
A linear regression was obtained with both diluents
(fig. 2).
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Fr ction of human serum
Fig. 2. Dilution of a human serum with:
o-o CEA-free Standard of the kit
β—ο CEA-free human serum
Potential sensitivity
To determine the lowest concentration of CEA sta-
tistically distinguishable from CEA-free specimens,
the zero Standard of the kit was assayed in single
measurements (n = 20). The detection limit of CEA
is defined s the three-fold Standard deviation of
absorbance of zero Standard calculated from the Stan-
dard curve. A sensitivity of less than 0.5 μg/l CEA
was noted (fig. 3).
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Specificity
Icteric, lipaemic, haemolytic sera and specimens from
patients suffering from rheumatic diseases and di-
alysed patients were diluted with normal human
serum and then spiked with CEA. The recovery of
CEA ranged from 94 to 104%. These results were
similar to those obtained in the recovery study (tab.
2). No interference by bilirübin (428 / ), lipids
(triacylglycerol concentration 10.26 mmol/1) haemo-
globin (l g/l), rheumatic factors or by dialysis cöuld
be observed.
The influence of drugs was assayed for the 37 effektive
components most frequently used (21) äs well äs
Diethylstilbestrol, Cisplatin, Doxorubicin, Etopösid,
Fluorouracil, Aminoglutethimid, Tamoxifen and
Ifosfamid. Normal serum was spiked with CEA and
with these substances. None of the dfugs affected the
reproducibility or accuracy of the assay.
Correlation studies
Table 3 shows a comparison of the results obtained
by En2ymun-Test® CEA and by 5 other CEA ässäys.
Regression parameters are calculated using a biomet-
ric regression procedüre in accordance with Passing &
Bablok (22). A good correlation was observed for the
enzyme immunoassäys and the self-developed radio^
immunoassay, except for the results of laboratory 8
(low CEA valües). Laboratories 7 and 9 did not
collect enough data for statistical evaluation; labora-
tories 6,11 and 12 did not take part in the correlation
trial. Two examples of gräphical correlations are dem-
onstrated in figures 4 and 5.
Distribution of CEA valües
CEA valües were determined in a group of 541
healthy control subjects (tab. 4) äs well äs in 590
patients with confirmed carcinoma and in 146
patients with non-malignant diseases (tab. 5). No
Tab. 3. Correlation between Enzymun-Test® CEA (x) and 6 different EIA and RIA kits (y) using a biometric regression procedufe.
Fig. 3. Sensitivity of the assay. The threefold Standard devia-
tion from the zero Standard absorbance (n = 20) was
calculated in g/l CEA.
Recovery
The recovery was assayed in spiked human sera.
Equal amounts of a solution of purified CEA (58
g/l) and human sera containing 0—5.47 g/l CEA
were mixed. The recovery valües obtained ranged
from 88 to 106% (tab. 2).
Tab. 2. Recovery study using serum samples diluted l + l (by
vol.) with a solution of purified CEA (58 g/l).
Sample
1
2
3
4
5
6
7
8
9
10
Serum
CEA
fog/l]
± 0
0.44
1.68
1.71
1.78
2.08
2.42
4.83
5.00
5.47
Measured
CEA
big/i]
27.85
29.67
30.01
31.64
29.12
30.62
30.76
29.74
28.96
28.18
Recovery
[%]
96
101
101
106
97
102
102
94
91
88
Lab-
ora-
tory
1
3
4
5
8
10^
13
14
15
15
Method
X
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
Enzymun-Test®
y
RIA, method 1
EIA MAK, method 3
EIA MAK, method 3
EIA MAK, method 3
EIA PAK, method 5
EIA MAK, method 3
EIA MAK, method 3
RIA, seif developed
EIA PAK, method 5
EIA PAK, method 2
N
73
74
58
96
60
45
106
32
149
116
Slope
b
0.842
0.981
1.091
0.988
1.222
1.091
1.043
0.955
1.008
1.004
Intercept
a
-0.356
0.015
-1.176
-0.650
0,636
-0.798
-0.043
-0.770
-0.034
0.693
CEA
[ §/1]
3.11
37.4
14.5
326
0.9
12.6
136
18.9
396
5.84
CEA
fcg/i]
2.34
35.6
14.5
320
1.7
1:2.6
136
16.6
535
6.61
r
0.953
0.981
0.979
0.995
0.633
0.933
0.998
0.941
0.997
0.998
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Υ = Χ-
θ 16 24 32 40 48
CEA (Enzymun-Test®CEA)
56 64
ΙΟ5 - Y= Χ
10 101 102 103
CEA (Enzymun-Test®CEA)
10* 10S
Fig. 4. Method comparison, CEA method 2.0— 64 μ§/1 CEA, Fig. 5. Method comparison, CEA method 5.0-56000 μg/l
total results, N = 116 CEA, total results, N = 149.
Tab. 4. Distribution of CEA values in healthy subjects.
Healthy subjects
Total1)
Men
Women
Non-smokers, total
Men
Women
Smokers, total
Men
Women
N
541
180
218
137
38
36
171
18
21
Min.
kg/l]
0
0
0
0.2
0.6
0.2
0.3
0.8
0.3
5th Percentile
kg/l]
0.1
0.1
0
0.6
0.7
0.7
0.8
1.0
0.6
Medi n
kg/l]
1.5
1.7
1.1
1.5
1.9
1.2
2.3
2.1
1.7
95th Percentile
kg/l]
4.9
6.1
4.0
3.6
4.5
3.2
8.2
7.1
4.4
Max.
kg/l]
10.5
8.2
5.0
4.6
4.6
3.6
10.5
8.2
4.9
Only part of the total number was differentiated in men, women, on-smokers and smokers.
Tab. 5. Distribution of CEA values in patients with malignant and non-malignant diseases.
N Min.
kg/l]
5ώ Percentile Medi n
kg/l] kg/l]
95lh Percentile Max.
kg/l] kg/l]
Carcinoma
Colorectal
Mammary
Pulmonary
Ovarian/Cervix
Medullary thyroid
Thyroid
Bladdef
61
168
36
34
17
74
200
0.8
0
0.1
0
0.1
0
0.3
0.8
0
0.2
0.2
0.2
0
0.3
70.0
2.2
8.9
1.9
22.9
0.1
1.7
5425.0
381.0
1634.5
20.0
1741.5
4.9
8.1
11180.0
1500.0
2250.0
32.3
3100.0
7.8
12.1
Non-malignant disease
Pancreatic
Hepatic/Cirrhosis
Dialysis
Other
14
27
59
46
0.4
0
0
0
0.5
0.3
0.1
0.2
1.4
1.9
2.4
2.5
4.3
6.4
7.8
8.9
5.3
6.9
10.2
11.1
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tumour classification or therapy was recorded for the
carcinoma patients. In healthy subjects a median of
1.5 §/1 CEA with 95% of all values between 0-4.9
§/1 CEA was recorded. The median of 2.3 §/1 CEA
for smokers was significantly higher (U-test, Mann^
Whitney) than the median of 1.5 g/l CEA for non-
smokers. Higher CEA values were found in men than
in women. CEA levels were elevated in colorectal,
mammary, pulmonary, medullary and thyroid carci-
noma. Slightly elevated values were observed in
patients with ovarian and cervical carcinoma. CEA
was not elevated in patients with thyroid or bladder
cancers. In the group of non-malignant patients CEA
values ranges from 4.3-8.9 g/l (95% of all values).
Follow-up studies
In retrospective follow-up studies, time courses show-
ing both increasing and decreasing CEA concentra-
tions in patients with colon carcinoma were deter-
mined with Eijzymun-Test® CEA and the roütine
assay (figs. 6, 7). A good correlation was found.
Discussion
The data of the present study indicate that CEA
serum levels determined with the new EIA exhibit a
high degree of correlation with other enzyme immu-
noassay or radioimmunoassay Systems. Some pre-
vious studies showed a good correlation between
different assay methods (8, 9, 10), whereas other
investigations (11,12) showed a low degree of correla-
tion or even lack of compärability. The poor correla-
tion repprted previously is partly due to the partial
structural similärity of CEA with non-specific cross-
reaction antigen (NCA) and biliary glycoprotein
(BGP). The good correlation öf the present assay
System with other methods suggestsrthat patients do
not have to be monitored by the same laboratofy.
This result is of interest for the treätment of patients.
In addition, a good specificity of the present CEA
EIA System was noted. It was found that the assay
was not influenced by icteric, haemolytie and lipaemic
serum conditions. Furthermöre, drugs used for the
therapy of cancer patients did not affect the reprodu-
cibility or accuracy of the assay. The multi-ceiitre
structure of this investigation also revealed the great
specificity of the present assay System, äs $hown by
CEA data obtained from normal subjects and from
patients with non-malignant diseases. A total of 95%
of all CEA levels recorded in serum of 541 normal
subjects were found to be between zero and 4.9 g/l
A median of all values was determined at 1.5 /l
CEA. In smokers the median was 2.3 §/1, signifi-
cantly higher than in non-smokers (1.5 g/l CEA).
But a cross-over of CEA concentrations is found
between acute benign diseases and eafly tumour sta-
ges, äs already well documented for other CEA assay
methods. The differentiation between benign diseases
and late tumour stages is clinically not important. It
was interesting to note that CEA levels were higher
in males than in females. No explanation can be given
for this at present.
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Fig. 6. Follow-up study of a patient with colon carcinoma.
A Enzymun-Test® CEA, o CEA, method 3.
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|. 7. Follow-up study of a patient with colon carcinoma.
A Enzymun-Test® CEA, · CEA,*method 3.
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Present data combine to suggest that this new CEA
EIA system, utilizing monoclonal antibodies, is a
valuable diagnostic tool. This multi-centre study has
shown that this assay System exhibits a high degree
of sensitivity, specificity and reproducibility. The high
degree of correlation with other assay Systems permits
the comparison of data obtained by various other
methods with this new CEA EIA.
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